



Express Mail Label No. EL 831679973 US

Date of Deposit: October 16, 2001

Page 1 of 2

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/867,847
	Filing Date	May 29, 2001
	First Named Inventor	Robert Chalifour
	Group Art Unit	1642
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	14445-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
20	A1*	5,985,242	11/16/99	Findeis <i>et al</i>	424	9.1	
	A2*	5,688,651	11/18/97	Solomon	435	7.1	
	A3*	5,721,130	02/24/98	Seubert <i>et al</i>	435	240.27	
	A4*	5,837,672	11/17/98	Schenk <i>et al</i>	514	2	
	A5*	5,891,991	04/06/99	Wasco <i>et al</i>	530	300	
	A6*	5,851,996	12/22/98	Kline	514	12	
	A7*	5,753,624	05/19/98	McMichael <i>et al</i>	514	12	
	A8*	5,514,548	05/07/96	Krebber <i>et al</i>	435	6	
	A9*	5,869,093	02/09/99	Weiner <i>et al</i>	424	451	
	A10*	5,470,951	11/28/95	Roberts	530	330	
	A11*	5,652,334	07/29/97	Roberts	530	330	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
20	B1*	WO	00/26238	Imperial College Innovations Limited	11/05/00		
	B2*	WO	95/12815	The Research Foundation of State University of New York	11/05/95		
	B3*	WO	98/22120	The Wistar Institute of Anatomy & Biology	28/05/98		
	B4*	WO	98/05350	Milkhaus Laboratory, Inc.	12/02/98		
	B5*	WO	99/58564	Gaudernack, Gustav	18/11/99		
	B6*	WO	00/43039	During, Matthew, John	27/07/00		
	B7*	WO	99/27944	Athena Neurosciences, Inc.	10/06/99		
	B8*	WO	99/60024	The University of Tennessee Research Corporation	25/11/99		
	B9*	WO	99/60021	Yeda Res. and Dev. Co., Ltd., and Mcinnis, Patricia, A.	25/11/99		
	B10*	WO	99/27949	Brigham and Women's Hospital	10/06/99		
	B11*	WO	95/05849	M&E Biotech A/S	02/03/95		
	B12*	WO	00/20027	M&E Biotech A/S	13/04/00		
	B13*	EP	0752886B1	M&E Biotech A/S	28/01/98		
	B14*	WO	95/31996	Milkhaus Laboratory	30/11/95		
	B15*	WO	95/05393	Hoess <i>et al.</i>	23/02/95		

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
B	B16*	WO	96/13583	Pack <i>et al</i>	09/05/96		
	B17*	WO	98/02462	Plückthun	22/01/98		
	B18*	WO	99/06587	Rudert <i>et al.</i>	11/02/99		
	B19*	WO	97/32017	Ilag <i>et al.</i>	04/09/97		
	B20*	WO	97/08320	Knappik <i>et al.</i>	06/03/97		
	B21*	WO	00/68263	Neurochem, Inc.	16/11/00		
	B22*	WO	98/08868	Praecis Pharm Inc.	05/03/98		
	B23*	WO	96/28471	Pharmaceutical Peptides Inc.	19/09/96		
	B24*	WO	97/21728	Karolinska Innovations AB	19/06/97		
	B25*	WO	95/08999	Roberts	06/04/95		
	B26*	WO	96/37621	Pack <i>et al.</i>	28/11/96		
	B27*	AU	199870091	Mouritsen and Elsner	30/07/98		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C	C1*	Younkin, "Amyloid beta vaccination: reduced plaques and improved cognition", Nat. Med. 2001 Jan; 7(1):18-9.
	C2*	Morgan <i>et al</i> , "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature, 2000 Dec. 21-28;408(6815):982-5.
	C3*	Pearson <i>et al</i> , "Beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," Nature, 2000 Dec. 21-28; 408(6815):979-82.
	C4*	Schenk <i>et al</i> , Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 1999 Jul. 8; 400(6740):173-7.
	C5*	Bard <i>et al</i> , "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nat. Med. 2000 Aug; 6(8):916-9.
	C6*	DeMattos <i>et al</i> , "Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease," Proc. Natl. Acad. Sci. USA 2001 Jul. 3 [ebpub ahead of print]
	C7*	Frenkel, "Immunization against Alzheimer's beta-amyloid plaques via EFRH phageadministration," Proc. Natl. Acad. Sci. USA 2000 Oct. 10;97(21):11455-9.
	C8*	Frenkel, "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine 2001 Mar. 21;19(17-19):2615-9.
	C9*	Van Regenmortel <i>et al</i> , "D-peptides as immunogens and diagnostic reagents," Curr. Opin. Biotechnol. 1998; Aug; 9(4):377-82.
	C10*	Sela <i>et al</i> , "Different roles of D-amino acids in immune phenomena," FASEB J 1998 May; 11(6):449-56.
	C11*	Tjernberg, <i>et al</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 Jul. 11; 272(28):17894.
	C12*	Tjernberg <i>et al</i> , "Arrest of beta-amyloid fibril formation by a pentapeptide ligand," J. Biol. Chem. 1996 Apr. 12; 271(15):8545-8.
	C13*	Tjernberg, <i>et al</i> , "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol. Chem. 1997 May 9; 272(19):12601-12605.
	C14*	Giulian, "The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer disease," J. Biol. Chem. 1998 Nov. 6; 273 (45):29719-29726.
	C15*	Flood <i>et al</i> , "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic affect of amyloid B protein," Proc. Natl. Acad. Sci. USA 1994; 91:380-384.
	C16*	Findeis <i>et al</i> , "Modified peptide inhibitors of amyloid B-peptide polymerization," Biochemistry 1999; 38:6791-6800.
	C17*	Benkirane <i>et al</i> , "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," The Journal of Biological Chemistry 1993; 268 (23):26279-26285.

Applicants: Robert Chalifour *et al.*
Serial Number: 09/867,847

Page 3 of 2

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/724,842, filed November 28, 2000, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	4-1-03
-----------------------	---	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1579254v1



Please type a plus sign (+) in this box



PTO/SB (12-9)
Approved for use through 9/30/00. OMB 0651-0047
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modifiable Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/867,847
	Filing Date	05/29/2001
	First Named Inventor	Chalifour
	Group Art Unit	1647
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	14445-501CIP

TECH CENTER 1600/2900

MAR 12 2002

RECEIVED

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<i>8</i>	A12	6,261,569	07/17/01	Comis, et al.			08/12/1997

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
<i>8</i>	B28	WO	94/05311	Deakin Research Limited	03/17/1994		
<i>8</i>	B29	WO	95/23166	Deakin Research Limited	08/31/1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>JSu</i>	Date Considered	4-1-03
--------------------	------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.